Physician profile
Patrick Matthiessen
NPI 1306833124
$77,181.52
in general payments reported to CMS, 2019-2025
39 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $15K · 2021: $11K · 2022: $5,331 · 2023: $6,266 · 2024: $22K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $19K · Consulting Fee: $9,863 · Food and Beverage: $8,656 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,406 · Travel and Lodging: $766 · Education: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $19,295.00 |
| Consulting Fee | $9,862.50 |
| Food and Beverage | $8,656.14 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,406.25 |
| Travel and Lodging | $765.72 |
| Education | $326.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $31,658.91 | 2023-2025 | |
| Abbvie INC. | $20,308.33 | 2021-2025 | |
| Allergan, INC. | $17,457.17 | 2020-2021 | |
| Lilly USA, LLC | $1,148.55 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Ucb, INC. | $777.45 | 2023-2025 | Nayzilam, Rystiggo, Briviact |
| Novartis Pharmaceuticals Corporation | $614.06 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $612.05 | 2022-2025 | Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $439.47 | 2025 | Ponvory |
| Biogen, INC. | $317.00 | 2019-2025 | Vumerity, Tysabri |
| Catalyst Pharmaceuticals, INC. | $282.90 | 2023-2025 | Fycompa |
| Emd Serono, INC. | $263.78 | 2020-2025 | Mavenclad |
| Sk Life Science, INC. | $252.41 | 2021-2025 | |
| Livanova USA, INC. | $233.64 | 2021-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Pfizer INC. | $224.03 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $196.26 | 2024-2025 | Rexulti |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $195.04 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Janssen Biotech, INC. | $190.63 | 2025 | |
| Argenx US, INC. | $188.40 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $163.37 | 2023-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Tg Therapeutics, INC. | $152.59 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $148.54 | 2023-2025 | Nuplazid |
| Lundbeck LLC | $135.84 | 2023-2025 | Rexulti, Vyepti |
| Alexion Pharmaceuticals, INC. | $135.58 | 2023-2025 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $130.12 | 2019-2020 | |
| Novo Nordisk INC | $119.70 | 2024 | |
| Silk Road Medical, INC. | $119.25 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Amgen INC. | $96.20 | 2019 | |
| Jazz Pharmaceuticals INC. | $95.46 | 2023-2024 | |
| Neurelis, INC. | $82.84 | 2023-2025 | Valtoco |
| Csl Behring | $82.11 | 2025 | Hizentra |
| Sumitomo Pharma America, INC. | $62.76 | 2023-2024 | Aptiom |
| Impel Pharmaceuticals INC. | $61.56 | 2023 | Trudhesa |
| Alnylam Pharmaceuticals INC. | $52.96 | 2024 | Onpattro |
| Neurocrine Biosciences, INC. | $50.92 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.99 | 2025 | Hyqvia |
| Biohaven Pharmaceutical Holding Company Ltd. | $39.00 | 2022 | |
| Impel Pharmaceuticals LLC | $20.62 | 2025 | Trudhesa |
| Kyowa Kirin, INC. | $17.04 | 2024 | Nourianz |
| Supernus Pharmaceuticals, INC. | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Matthiessen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.